Second Open Label Extension to Bridging Study CTBM100C2303
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Successfully Completed Participation in Study CTBM100C2303E1
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Pseudomonas Aeruginosa and Pulmonary Infections, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 8 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bucharest, Romania , Durban, South Africa , Kaunas, Lithuania , Kazan', Russia , Moscow, Russia , Pleven, Bulgaria , Plovdiv, Bulgaria , Riga, Latvia , Saint Petersburg, Russia , Samara, Russia and 7 more locations